CoChat
Sign Up
Cited by 744Probiotics and Fermented FoodsGut microbiota and healthReproductive tract infections research

Role of Lactobacillus reuteri in Human Health and Diseases

Open access
Mu, Qinghui, Tavella, Vincent J., Luo, Xin M.·2018·Frontiers in Microbiology
DOI 10.3389/fmicb.2018.00757PMC PMC5917019
Open this paper in CoChat — free accountOpen PDF

Abstract

Lactobacillus reuteri (L. reuteri) is a well-studied probiotic bacterium that can colonize a large number of mammals. In humans, L. reuteri is found in different body sites, including the gastrointestinal tract, urinary tract, skin and breast milk. The abundance of L. reuteri varies among different individuals. Several beneficial effects of L. reuteri have been noted. Firstly, L. reuteri can produce antimicrobial molecules, such as organic acids, ethanol and reuterin. Due to its antimicrobial activity, L. reuteri is able to inhibit the colonization of pathogenic microbes and remodel the commensal microbiota composition in the host. Secondly, L. reuteri can benefit the host immune system. For instance, some L. reuteri strains can reduce the production of pro-inflammatory cytokines while promoting regulatory T cell development and function. Thirdly, bearing the ability to strengthen the intestinal barrier, the colonization of L. reuteri may decrease the microbial translocation from the gut lumen to the tissues. Microbial translocation across the intestinal epithelium has been hypothesized as an initiator of inflammation. Therefore, inflammatory diseases, including those located in the gut as well as in remote tissues, may be ameliorated by increasing the colonization of L. reuteri. Notably, the decrease in the abundance of L. reuteri in humans in the past decades is correlated with an increase in the incidences of inflammatory diseases over the same period of time. Direct supplementation or prebiotic modulation of L. reuteri may be an attractive preventive and/or therapeutic avenue against inflammatory diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2018.00757

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The adhesion capacity to the epithelium provides for the ability of bacterial strains to continue their antimicrobial activities over time by maintaining their presence in the host.

    “Furthermore, the adhesion capacity to the epithelium provides for the ability of bacterial strains to continue their antimicrobial activities over time by maintaining their presence in the host [14, 15].”

    From EVALUATION OF ADHESIVE AND AGGREGATION PROPERTIES OF LACTIC ACID BACTERIA ISOLATED FROM DIFFERENT BIOTOPES (2025) · cites this paper as [15]

    The ‘Gut Colonization of L. reuteri’ section describes epithelial adhesion and its association with colonization, while ‘Production of Metabolites With Health-Promoting Effect’ describes antimicrobial substances made by some L. reuteri strains. The paper does not establish that adhesion maintains those strains’ antimicrobial activity over time, or make that claim for bacterial strains generally. The indexed passages provide section labels but no page numbers. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 216

  1. Abediankenari S. Ghasemi M. (2009). Generation of immune inhibitory dendritic cells and CD4+T regulatory cells inducing by TGF-beta. Iran. J. Allergy Asthma Immunol. 8 25– 30. 19279356
  2. Abhisingha M. Dumnil J. Pitaksutheepong C. (2017). Selection of potential probiotic Lactobacillus with inhibitory activity against Salmonella and fecal coliform bacteria. Probiotics Antimicrob. Proteins 10.1007/s12602-017-9304-8 [Epub ahead of print]. 28712023 · DOI
  3. Abrahamsson T. R. Jakobsson T. Bjorksten B. Oldaeus G. Jenmalm M. C. (2013). No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. Pediatr. Allergy Immunol. 24 556– 561. 10.1111/pai.12104 23902407 · DOI
  4. Abrahamsson T. R. Jakobsson T. Bottcher M. F. Fredrikson M. Jenmalm M. C. Bjorksten B. (2007). Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J. Allergys Clin. Immunol. 119 1174– 1180. 10.1016/j.jaci.2007.01.007 17349686 · DOI
  5. Agustina R. Kok F. J. van de Rest O. Fahmida U. Firmansyah A. Lukito W. (2012). Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics 129 e1155– e1164. 10.1542/peds.2011-1379 22492764 · DOI
  6. Amara A. A. Shibl A. (2015). Role of probiotics in health improvement, infection control and disease treatment and management. Saudi Pharm. J. 23 107– 114. 10.1016/j.jsps.2013.07.001 25972729 PMC4421088 · DOI
  7. Ang L. Y. Too H. K. Tan E. L. Chow T. K. Shek P. C. Tham E. (2016). Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines. Virol. J. 13: 111. 10.1186/s12985-016-0567-6 27341804 PMC4920999 · DOI
  8. Armougom F. Henry M. Vialettes B. Raccah D. Raoult D. (2009). Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One 4: e7125. 10.1371/journal.pone.0007125 19774074 PMC2742902 · DOI · Paper page
  9. Barrett E. Ross R. P. O’Toole P. W. Fitzgerald G. F. Stanton C. (2012). gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J. Appl. Microbiol. 113 411– 417. 10.1111/j.1365-2672.2012.05344.x 22612585 · DOI · Paper page
  10. Bene K. Varga Z. Petrov V. O. Boyko N. Rajnavolgyi E. (2017). Gut microbiota species can provoke both inflammatory and tolerogenic immune responses in human dendritic cells mediated by retinoic acid receptor alpha ligation. Front. Immunol. 8: 427. 10.3389/fimmu.2017.00427 28458670 PMC5394128 · DOI
  11. Bervoets L. Van Hoorenbeeck K. Kortleven I. Van Noten C. Hens N. Vael C. (2013). Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog. 5: 10. 10.1186/1757-4749-5-10 23631345 PMC3658928 · DOI
  12. Bisanz J. E. Seney S. McMillan A. Vongsa R. Koenig D. Wong L. (2014). A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal women. PLoS One 9: e104511. 10.1371/journal.pone.0104511 25127240 PMC4134203 · DOI
  13. Bottcher M. F. Abrahamsson T. R. Fredriksson M. Jakobsson T. Bjorksten B. (2008). Low breast milk TGF-beta2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy. Pediatr. Allergy Immunol. 19 497– 504. 10.1111/j.1399-3038.2007.00687.x 18221472 · DOI
  14. Braathen G. Ingildsen V. Twetman S. Ericson D. Jorgensen M. R. (2017). Presence of Lactobacillus reuteri in saliva coincide with higher salivary IgA in young adults after intake of probiotic lozenges. Benef. Microbes 8 17– 22. 10.3920/BM2016.0081 27873545 · DOI
  15. Braegger C. Chmielewska A. Decsi T. Kolacek S. Mihatsch W. Moreno L. (2011). Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J. Pediatr. Gastroenterol. Nutr. 52 238– 250. 10.1097/MPG.0b013e3181fb9e80 21150647 · DOI
  16. Brenner T. A. Rice T. A. Anderson E. D. Percopo C. M. Rosenberg H. F. (2016). Immortalized MH-S cells lack defining features of primary alveolar macrophages and do not support mouse pneumovirus replication. Immunol. Lett. 172 106– 112. 10.1016/j.imlet.2016.02.012 26916143 PMC4846554 · DOI
  17. Britton R. A. Irwin R. Quach D. Schaefer L. Zhang J. Lee T. (2014). Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J. Cell. Physiol. 229 1822– 1830. 10.1002/jcp.24636 24677054 PMC4129456 · DOI · Paper page
  18. Brun P. Giron M. C. Qesari M. Porzionato A. Caputi V. Zoppellaro C. (2013). Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 145 1323– 1333. 10.1053/j.gastro.2013.08.047 23994200 · DOI · Paper page
  19. Buffington S. A. Di Prisco G. V. Auchtung T. A. Ajami N. J. Petrosino J. F. Costa-Mattioli M. (2016). Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165 1762– 1775. 10.1016/j.cell.2016.06.001 27315483 PMC5102250 · DOI · Paper page
  20. Burge G. Saulou-Berion C. Moussa M. Pollet B. Flourat A. Allais F. (2015). Diversity of Lactobacillus reuteri strains in converting glycerol into 3-hydroxypropionic acid. Appl. Biochem. Biotechnol. 177 923– 939. 10.1007/s12010-015-1787-8 26319567 · DOI
  21. Cadieux P. Wind A. Sommer P. Schaefer L. Crowley K. Britton R. A. (2008). Evaluation of reuterin production in urogenital probiotic Lactobacillus reuteri RC-14. Appl. Environ. Microbiol. 74 4645– 4649. 10.1128/AEM.00139-08 18539802 PMC2519358 · DOI
  22. Camilleri M. Nadeau A. Lamsam J. Nord S. L. Ryks M. Burton D. (2010). Understanding measurements of intestinal permeability in healthy humans with urine lactulose and mannitol excretion. Neurogastroenterol. Motil. 22 e15– e26. 10.1111/j.1365-2982.2009.01361.x 19614866 PMC2802677 · DOI
  23. Cekola P. L. Czerkies L. A. Storm H. M. Wang M. H. Roberts J. Saavedra J. M. (2015). Growth and tolerance of term infants fed formula with probiotic Lactobacillus reuteri. Clin. Pediatr. 54 1175– 1184. 10.1177/0009922815574076 25758426 · DOI
  24. Cervantes-Barragan L. Chai J. N. Tianero M. D. Di Luccia B. Ahern P. P. Merriman J. (2017). Lactobacillus reuteri induces gut intraepithelial CD4+CD8alphaalpha+ T cells. Science 357 806– 810. 10.1126/science.aah5825 28775213 PMC5687812 · DOI · Paper page
  25. Chau K. Lau E. Greenberg S. Jacobson S. Yazdani-Brojeni P. Verma N. (2015). Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J. Pediatr. 166 74– 78. 10.1016/j.jpeds.2014.09.020 25444531 · DOI
  26. Chen G. Chen J. (2013). A novel cell modification method used in biotransformation of glycerol to 3-HPA by Lactobacillus reuteri. Appl. Microbiol. Biotechnol. 97 4325– 4332. 10.1007/s00253-013-4723-2 23359000 · DOI
  27. Chen X. Y. Woodward A. Zijlstra R. T. Ganzle M. G. (2014). Exopolysaccharides synthesized by Lactobacillus reuteri protect against enterotoxigenic Escherichia coli in piglets. Appl. Environ. Microbiol. 80 5752– 5760. 10.1128/AEM.01782-14 25015886 PMC4178603 · DOI
  28. Cherian P. T. Wu X. Yang L. Scarborough J. S. Singh A. P. Alam Z. A. (2015). Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection. J. Antimicrob. Chemother. 70 3061– 3069. 10.1093/jac/dkv231 26286574 PMC4677261 · DOI
  29. Chung H. J. Yu J. G. Lee I. A. Liu M. J. Shen Y. F. Sharma S. P. (2016). Intestinal removal of free fatty acids from hosts by Lactobacilli for the treatment of obesity. FEBS Open Bio 6 64– 76. 10.1002/2211-5463.12024 27047743 PMC4794792 · DOI
  30. Cleusix V. Lacroix C. Vollenweider S. Duboux M. Le Blay G. (2007). Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol. 7: 101. 10.1186/1471-2180-7-101 17997816 PMC2222629 · DOI
  31. Dahiya D. K. Renuka Puniya M. Shandilya U. K. Dhewa T. Kumar N. (2017). Gut microbiota modulation and its relationship with obesity using prebiotic fibers and probiotics: a review. Front. Microbiol. 8: 563. 10.3389/fmicb.2017.00563 28421057 PMC5378938 · DOI
  32. De Benedetto A. Rafaels N. M. McGirt L. Y. Ivanov A. I. Georas S. N. Cheadle C. (2011). Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127 771. e7– 786.e7. 10.1016/j.jaci.2010.10.018 21163515 PMC3049863 · DOI
  33. de Oliveira G. L. V. Leite A. Z. Higuchi B. S. Gonzaga M. I. Mariano V. S. (2017). Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology 152 1– 12. 10.1111/imm.12765 28556916 PMC5543467 · DOI
  34. del Campo R. Garriga M. Perez-Aragon A. Guallarte P. Lamas A. Maiz L. (2014). Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J. Cyst. Fibros. 13 716– 722. 10.1016/j.jcf.2014.02.007 24636808 · DOI
  35. Diaz M. Ladero V. del Rio B. Redruello B. Fernandez M. Martin M. C. (2016). Biofilm-forming capacity in biogenic amine-producing bacteria isolated from dairy products. Front. Microbiol. 7: 591. 10.3389/fmicb.2016.00591 27242675 PMC4864664 · DOI
  36. Dicksved J. Schreiber O. Willing B. Petersson J. Rang S. Phillipson M. (2012). Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. PLoS One 7: e46399. 10.1371/journal.pone.0046399 23029509 PMC3459901 · DOI
  37. Dinleyici E. C. Dalgic N. Guven S. Metin O. Yasa O. Kurugol Z. (2015). Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J. Pediatr. 91 392– 396. 10.1016/j.jped.2014.10.009 25986615 · DOI
  38. Dinleyici E. C. Probage Study Group Vandenplas Y. (2014). Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr. 103 e300– e305. 10.1111/apa.12617 24579935 · DOI
  39. Dore M. P. Cuccu M. Pes G. M. Manca A. Graham D. Y. (2014). Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern. Emerg. Med. 9 649– 654. 10.1007/s11739-013-1013-z 24178436 · DOI
  40. Dore M. P. Soro S. Rocchi C. Loria M. F. Bibbo S. Pes G. M. (2016). Inclusion of Lactobacillus reuteri in the treatment of Helicobacter pylori in Sardinian patients: a case report series. Medicine 95: e3411. 10.1097/MD.0000000000003411 27082621 PMC4839865 · DOI
  41. Duar R. M. Lin X. B. Zheng J. Martino M. E. Grenier T. Perez-Munoz M. E. (2017). Lifestyles in transition: evolution and natural history of the genus Lactobacillus. FEMS Microbiol. Rev. 41(Suppl. 1) S27– S48. 10.1093/femsre/fux030 28673043 · DOI
  42. Edwards M. R. Dai R. Heid B. Cecere T. E. Khan D. Mu Q. (2017). Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice. Int. Immunol. 29 263– 276. 10.1093/intimm/dxx033 28637300 PMC5890898 · DOI
  43. Engels C. Schwab C. Zhang J. Stevens M. J. Bieri C. Ebert M. O. (2016). Acrolein contributes strongly to antimicrobial and heterocyclic amine transformation activities of reuterin. Sci. Rep. 6: 36246. 10.1038/srep36246 27819285 PMC5098142 · DOI
  44. Ericson D. Hamberg K. Bratthall G. Sinkiewicz-Enggren G. Ljunggren L. (2013). Salivary IgA response to probiotic bacteria and mutans streptococci after the use of chewing gum containing Lactobacillus reuteri. Pathog. Dis. 68 82– 87. 10.1111/2049-632X.12048 23737255 · DOI
  45. Esmaeili S. A. Mahmoudi M. Momtazi A. A. Sahebkar A. Doulabi H. Rastin M. (2017). Tolerogenic probiotics: potential immunoregulators in Systemic Lupus Erythematosus. J. Cell. Physiol. 232 1994– 2007. 10.1002/jcp.25748 27996081 · DOI
  46. Fåk F. Bäckhed F. (2012). Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice. PLoS One 7: e46837. 10.1371/journal.pone.0046837 23056479 PMC3467285 · DOI
  47. Francavilla R. Lionetti E. Castellaneta S. Ciruzzi F. Indrio F. Masciale A. (2012). Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea–a double-blind study. Aliment. Pharmacol. Ther. 36 363– 369. 10.1111/j.1365-2036.2012.05180.x 22680836 · DOI
  48. Francavilla R. Lionetti E. Castellaneta S. P. Magista A. M. Maurogiovanni G. Bucci N. (2008). Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13 127– 134. 10.1111/j.1523-5378.2008.00593.x 18321302 · DOI
  49. Francavilla R. Polimeno L. Demichina A. Maurogiovanni G. Principi B. Scaccianoce G. (2014). Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J. Clin. Gastroenterol. 48 407– 413. 10.1097/MCG.0000000000000007 24296423 · DOI
  50. Franceschi F. Cazzato A. Nista E. C. Scarpellini E. Roccarina D. Gigante G. (2007). Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 12(Suppl. 2) 59– 63. 10.1111/j.1523-5378.2007.00565.x 17991178 · DOI
  51. Frese S. A. Benson A. K. Tannock G. W. Loach D. M. Kim J. Zhang M. (2011). The evolution of host specialization in the vertebrate gut symbiont Lactobacillus reuteri. PLoS Genet. 7: e1001314. 10.1371/journal.pgen.1001314 21379339 PMC3040671 · DOI
  52. Frese S. A. Mackenzie D. A. Peterson D. A. Schmaltz R. Fangman T. Zhou Y. (2013). Molecular characterization of host-specific biofilm formation in a vertebrate gut symbiont. PLoS Genet. 9: e1004057. 10.1371/journal.pgen.1004057 24385934 PMC3873254 · DOI
  53. Galley J. D. Mackos A. R. Varaljay V. A. Bailey M. T. (2017). Stressor exposure has prolonged effects on colonic microbial community structure in Citrobacter rodentium-challenged mice. Sci. Rep. 7: 45012. 10.1038/srep45012 28344333 PMC5366811 · DOI
  54. Galley J. D. Nelson M. C. Yu Z. Dowd S. E. Walter J. Kumar P. S. (2014). Exposure to a social stressor disrupts the community structure of the colonic mucosa-associated microbiota. BMC Microbiol. 14: 189. 10.1186/1471-2180-14-189 25028050 PMC4105248 · DOI
  55. Ganzle M. G. Vogel R. F. (2003). Studies on the mode of action of reutericyclin. Appl. Environ. Microbiol. 69 1305– 1307. 10.1128/AEM.69.2.1305-1307.2003 12571063 PMC143594 · DOI
  56. Gao C. Major A. Rendon D. Lugo M. Jackson V. Shi Z. (2015). Histamine H2 Receptor-Mediated Suppression of Intestinal Inflammation by Probiotic Lactobacillus reuteri. mBio 6: e01358-15. 10.1128/mBio.01358-15 26670383 PMC4701830 · DOI · Paper page
  57. Garcia Rodenas C. L. Lepage M. Ngom-Bru C. Fotiou A. Papagaroufalis K. Berger B. (2016). Effect of formula containing Lactobacillus reuteri DSM 17938 on fecal microbiota of infants born by cesarean-section. J. Pediatr. Gastroenterol. Nutr. 63 681– 687. 10.1097/MPG.0000000000001198 27035371 · DOI
  58. Garofoli F. Civardi E. Indrio F. Mazzucchelli I. Angelini M. Tinelli C. (2014). The early administration of Lactobacillus reuteri DSM 17938 controls regurgitation episodes in full-term breastfed infants. Int. J. Food Sci. Nutr. 65 646– 648. 10.3109/09637486.2014.898251 24635827 · DOI
  59. Genis S. Sanchez-Chardi A. Bach A. Fabregas F. Aris A. (2017). A combination of lactic acid bacteria regulates Escherichia coli infection and inflammation of the bovine endometrium. J. Dairy Sci. 100 479– 492. 10.3168/jds.2016-11671 27837977 · DOI
  60. Gille C. Boer B. Marschal M. Urschitz M. S. Heinecke V. Hund V. (2016). Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial. Am. J. Obstet. Gynecol. 215 608. e1– 608.e7. 10.1016/j.ajog.2016.06.021 27342046 · DOI
  61. Gopi G. R. Ganesh N. Pandiaraj S. Sowmiya B. Brajesh R. G. Ramalingam S. (2015). A study on enhanced expression of 3-hydroxypropionic acid pathway genes and impact on its production in Lactobacillus reuteri. Food Technol. Biotechnol. 53 331– 336. 10.17113/ftb.53.03.15.3976 27904365 PMC5068375 · DOI
  62. Greifova G. Majekova H. Greif G. Body P. Greifova M. Dubnickova M. (2017). Analysis of antimicrobial and immunomodulatory substances produced by heterofermentative Lactobacillus reuteri. Folia Microbiol. 62 515– 524. 10.1007/s12223-017-0524-9 28401403 · DOI
  63. Grover S. Rastogi A. Singh J. Rajbongshi A. Bihari C. (2014). Spectrum of histomorphologic findings in liver in patients with SLE: a review. Hepat. Res. Treat. 2014: 562979. 10.1155/2014/562979 25136456 PMC4130189 · DOI
  64. Gu Q. Zhang C. Song D. Li P. Zhu X. (2015). Enhancing vitamin B12 content in soy-yogurt by Lactobacillus reuteri. Int. J. Food Microbiol. 206 56– 59. 10.1016/j.ijfoodmicro.2015.04.033 25955289 · DOI
  65. Gunning A. P. Kavanaugh D. Thursby E. Etzold S. MacKenzie D. A. Juge N. (2016). Use of atomic force microscopy to study the multi-modular interaction of bacterial adhesins to mucins. Int. J. Mol. Sci. 17: E1854. 10.3390/ijms17111854 27834807 PMC5133854 · DOI
  66. Gutierrez-Castrellon P. Lopez-Velazquez G. Diaz-Garcia L. Jimenez-Gutierrez C. Mancilla-Ramirez J. Estevez-Jimenez J. (2014). Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 133 e904– e909. 10.1542/peds.2013-0652 24639271 · DOI
  67. Harakeh S. M. Khan I. Kumosani T. Barbour E. Almasaudi S. B. Bahijri S. M. (2016). Gut microbiota: a contributing factor to obesity. Front. Cell. Infect. Microbiol. 6: 95 10.3389/fcimb.2016.00095 PMC5003832 27625997 · DOI
  68. Hemarajata P. Gao C. Pflughoeft K. J. Thomas C. M. Saulnier D. M. Spinler J. K. (2013). Lactobacillus reuteri-specific immunoregulatory gene rsiR modulates histamine production and immunomodulation by Lactobacillus reuteri. J. Bacteriol. 195 5567– 5576. 10.1128/JB.00261-13 24123819 PMC3889603 · DOI
  69. Hill C. Guarner F. Reid G. Gibson G. R. Merenstein D. J. Pot B. (2014). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11 506– 514. 10.1038/nrgastro.2014.66 24912386 · DOI
  70. Holz C. Busjahn A. Mehling H. Arya S. Boettner M. Habibi H. (2015). Significant reduction in Helicobacter pylori load in humans with non-viable Lactobacillus reuteri DSM17648: a pilot study. Probiotics Antimicrob. Proteins 7 91– 100. 10.1007/s12602-014-9181-3 25481036 PMC4415890 · DOI
  71. Hou C. Wang Q. Zeng X. Yang F. Zhang J. Liu H. (2014). Complete genome sequence of Lactobacillus reuteri I5007, a probiotic strain isolated from healthy piglet. J. Biotechnol. 179 63– 64. 10.1016/j.jbiotec.2014.03.019 24685642 · DOI
  72. Hou C. Zeng X. Yang F. Liu H. Qiao S. (2015). Study and use of the probiotic Lactobacillus reuteri in pigs: a review. J. Anim. Sci. Biotechnol. 6: 14. 10.1186/s40104-015-0014-3 25954504 PMC4423586 · DOI
  73. Hoy-Schulz Y. E. Jannat K. Roberts T. Zaidi S. H. Unicomb L. Luby S. (2016). Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial. BMC Complement. Altern. Med. 16: 44. 10.1186/s12906-016-1016-1 26832746 PMC4736167 · DOI
  74. Hsieh F. C. Lan C. C. Huang T. Y. Chen K. W. Chai C. Y. Chen W. T. (2016). Heat-killed and live Lactobacillus reuteri GMNL-263 exhibit similar effects on improving metabolic functions in high-fat diet-induced obese rats. Food Funct. 7 2374– 2388. 10.1039/c5fo01396h 27163114 · DOI
  75. Hsu T. C. Huang C. Y. Chiang S. Y. Lai W. X. Tsai C. H. Tzang B. S. (2008). Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice. Eur. J. Pharmacol. 579 382– 389. 10.1016/j.ejphar.2007.10.059 18031733 · DOI
  76. Hsu T. C. Huang C. Y. Liu C. H. Hsu K. C. Chen Y. H. Tzang B. S. (2017). Lactobacillus paracasei GMNL-32, Lactobacillus reuteri GMNL-89 and L. reuteri GMNL-263 ameliorate hepatic injuries in lupus-prone mice. Br. J. Nutr. 117 1066– 1074. 10.1017/S0007114517001039 28502277 · DOI
  77. Imase K. Tanaka A. Tokunaga K. Sugano H. Ishida H. Takahashi S. (2007). Lactobacillus reuteri tablets suppress Helicobacter pylori infection–a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi 81 387– 393. 10.11150/kansenshogakuzasshi1970.81.387 17695792 · DOI
  78. Indrio F. Riezzo G. Raimondi F. Bisceglia M. Cavallo L. Francavilla R. (2008). The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J. Pediatr. 152 801– 806. 10.1016/j.jpeds.2007.11.005 18492520 · DOI
  79. Indrio F. Riezzo G. Raimondi F. Bisceglia M. Cavallo L. Francavilla R. (2009). Effects of probiotic and prebiotic on gastrointestinal motility in newborns. J. Physiol. Pharmacol. 60(Suppl. 6) 27– 31. 20224148
  80. Iniesta M. Herrera D. Montero E. Zurbriggen M. Matos A. R. Marin M. J. (2012). Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. J. Clin. Periodontol. 39 736– 744. 10.1111/j.1600-051X.2012.01914.x 22694350 · DOI
  81. Islam S. U. (2016). Clinical uses of probiotics. Medicine 95: e2658. 10.1097/MD.0000000000002658 26844491 PMC4748908 · DOI
  82. Jacobsen C. N. Rosenfeldt Nielsen V. Hayford A. E. Moller P. L. Michaelsen K. F. Paerregaard A. (1999). Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl. Environ. Microbiol. 65 4949– 4956. 10543808 PMC91666
  83. Jensen H. Roos S. Jonsson H. Rud I. Grimmer S. van Pijkeren J. P. (2014). Role of Lactobacillus reuteri cell and mucus-binding protein A (CmbA) in adhesion to intestinal epithelial cells and mucus in vitro. Microbiology 160(Pt 4) 671– 681. 10.1099/mic.0.073551-0 24473252 PMC7336543 · DOI
  84. Jones M. L. Martoni C. J. Di Pietro E. Simon R. R. Prakash S. (2012a). Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial. Regul. Toxicol. Pharmacol. 63 313– 320. 10.1016/j.yrtph.2012.04.003 22561556 · DOI · Paper page
  85. Jones M. L. Martoni C. J. Tamber S. Parent M. Prakash S. (2012c). Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study. Food Chem. Toxicol. 50 2216– 2223. 10.1016/j.fct.2012.03.010 22425689 · DOI
  86. Jones S. E. Versalovic J. (2009). Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 9: 35. 10.1186/1471-2180-9-35 19210794 PMC2653509 · DOI
  87. Jorgensen M. R. Keller M. K. Kragelund C. Hamberg K. Ericson D. Nielsen C. H. (2016). Lactobacillus reuteri supplements do not affect salivary IgA or cytokine levels in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over trial. Acta Odontol. Scand. 74 399– 404. 10.3109/00016357.2016.1169439 27104984 · DOI
  88. Kamiya T. Wang L. Forsythe P. Goettsche G. Mao Y. Wang Y. (2006). Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55 191– 196. 10.1136/gut.2005.070987 16361309 PMC1856513 · DOI · Paper page
  89. Kandler O. Stetter K. O. Kohl R. (1980). Lactobacillus reuteri sp. nov., a new species of heterofermentative lactobacilli. Zentralbl. Bakteriol. Hyg. I Abt Orig. 1 264– 269. 10.1016/S0172-5564(80)80007-8 · DOI
  90. Karaffova V. Csank T. Mudronova D. Kiraly J. Revajova V. Gancarcikova S. (2017). Influence of Lactobacillus reuteri L26 Biocenol on immune response against porcine circovirus type 2 infection in germ-free mice. Benef. Microbes 8 367– 378. 10.3920/BM2016.0114 28504566 · DOI
  91. Karimi K. Inman M. D. Bienenstock J. Forsythe P. (2009). Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am. J. Respir. Crit. Care Med. 179 186– 193. 10.1164/rccm.200806-951OC 19029003 · DOI
  92. Kechagia M. Basoulis D. Konstantopoulou S. Dimitriadi D. Gyftopoulou K. Skarmoutsou N. (2013). Health benefits of probiotics: a review. ISRN Nutr. 2013: 481651. 10.5402/2013/481651 24959545 PMC4045285 · DOI
  93. Keller M. K. Nohr Larsen I. Karlsson I. Twetman S. (2014). Effect of tablets containing probiotic bacteria (Lactobacillus reuteri) on early caries lesions in adolescents: a pilot study. Benef. Microbes 5 403– 407. 10.3920/BM2013.0089 24889893 · DOI
  94. Kleerebezem M. Hols P. Bernard E. Rolain T. Zhou M. Siezen R. J. (2010). The extracellular biology of the lactobacilli. FEMS Microbiol. Rev. 34 199– 230. 10.1111/j.1574-6976.2010.00208.x 20088967 · DOI
  95. Koleva P. T. Bridgman S. L. Kozyrskyj A. L. (2015). The infant gut microbiome: evidence for obesity risk and dietary intervention. Nutrients 7 2237– 2260. 10.3390/nu7042237 25835047 PMC4425142 · DOI
  96. Krumbeck J. A. Marsteller N. L. Frese S. A. Peterson D. A. Ramer-Tait A. E. Hutkins R. W. (2016). Characterization of the ecological role of genes mediating acid resistance in Lactobacillus reuteri during colonization of the gastrointestinal tract. Environ. Microbiol. 18 2172– 2184. 10.1111/1462-2920.13108 26530032 · DOI
  97. Kunze W. A. Mao Y. K. Wang B. Huizinga J. D. Ma X. Forsythe P. (2009). Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium-dependent potassium channel opening. J. Cell Mol. Med. 13 2261– 2270. 10.1111/j.1582-4934.2009.00686.x 19210574 PMC6529958 · DOI · Paper page
  98. Lai N. Y. Mills K. Chiu I. M. (2017). Sensory neuron regulation of gastrointestinal inflammation and bacterial host defence. J. Intern. Med. 282 5– 23. 10.1111/joim.12591 28155242 PMC5474171 · DOI
  99. Lesbros-Pantoflickova D. Corthesy-Theulaz I. Blum A. L. (2007). Helicobacter pylori and probiotics. J. Nutr. 137(3 Suppl. 2) 812S– 818S. 10.1093/jn/137.3.812S 17311980 · DOI
  100. Li X. J. Yue L. Y. Guan X. F. Qiao S. Y. (2008). The adhesion of putative probiotic lactobacilli to cultured epithelial cells and porcine intestinal mucus. J. Appl. Microbiol. 104 1082– 1091. 10.1111/j.1365-2672.2007.03636.x 18081774 · DOI
  101. Liao P. H. Kuo W. W. Hsieh D. J. Yeh Y. L. Day C. H. Chen Y. H. (2016). Heat-killed Lactobacillus reuteri GMNL-263 prevents epididymal fat accumulation and cardiac injury in high-calorie diet-fed rats. Int. J. Med. Sci. 13 569– 577. 10.7150/ijms.15597 27499689 PMC4974905 · DOI
  102. Linares D. M. Gomez C. Renes E. Fresno J. M. Tornadijo M. E. Ross R. P. (2017). Lactic acid bacteria and bifidobacteria with potential to design natural biofunctional health-promoting dairy foods. Front. Microbiol. 8: 846. 10.3389/fmicb.2017.00846 28572792 PMC5435742 · DOI · Paper page
  103. Lionetti E. Miniello V. L. Castellaneta S. P. Magista A. M. de Canio A. Maurogiovanni G. (2006). Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment. Pharmacol. Ther. 24 1461– 1468. 10.1111/j.1365-2036.2006.03145.x 17032283 · DOI
  104. Liu F. Wang X. Shi H. Wang Y. Xue C. Tang Q. J. (2017). Polymannuronic acid ameliorated obesity and inflammation associated with a high-fat and high-sucrose diet by modulating the gut microbiome in a murine model. Br. J. Nutr. 117 1332– 1342. 10.1017/S0007114517000964 28528593 · DOI
  105. Liu H. Hou C. Wang G. Jia H. Yu H. Zeng X. (2017). Lactobacillus reuteri I5007 modulates intestinal host defense peptide expression in the model of IPEC-J2 cells and neonatal piglets. Nutrients 9: E559. 10.3390/nu9060559 28561758 PMC5490538 · DOI
  106. Liu Y. Fatheree N. Y. Dingle B. M. Tran D. Q. Rhoads J. M. (2013). Lactobacillus reuteri DSM 17938 changes the frequency of Foxp3+ regulatory T cells in the intestine and mesenteric lymph node in experimental necrotizing enterocolitis. PLoS One 8: e56547. 10.1371/journal.pone.0056547 23437165 PMC3577854 · DOI
  107. Liu Y. Tran D. Q. Fatheree N. Y. Marc Rhoads J. (2014). Lactobacillus reuteri DSM 17938 differentially modulates effector memory T cells and Foxp3+ regulatory T cells in a mouse model of necrotizing enterocolitis. Am. J. Physiol. Gastrointest. Liver Physiol. 307 G177– G186. 10.1152/ajpgi.00038.2014 24852566 PMC4101683 · DOI
  108. Livingston M. Loach D. Wilson M. Tannock G. W. Baird M. (2010). Gut commensal Lactobacillus reuteri 100-23 stimulates an immunoregulatory response. Immunol. Cell Biol. 88 99– 102. 10.1038/icb.2009.71 19786979 · DOI
  109. Lorea Baroja M. Kirjavainen P. V. Hekmat S. Reid G. (2007). Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin. Exp. Immunol. 149 470– 479. 10.1111/j.1365-2249.2007.03434.x 17590176 PMC2219330 · DOI
  110. Ma X. Mao Y. K. Wang B. Huizinga J. D. Bienenstock J. Kunze W. (2009). Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am. J. Physiol. Gastrointest. Liver Physiol. 296 G868– G875. 10.1152/ajpgi.90511.2008 19179624 · DOI
  111. Mackenzie D. A. Jeffers F. Parker M. L. Vibert-Vallet A. Bongaerts R. J. Roos S. (2010). Strain-specific diversity of mucus-binding proteins in the adhesion and aggregation properties of Lactobacillus reuteri. Microbiology 156(Pt 11) 3368– 3378. 10.1099/mic.0.043265-0 20847011 · DOI
  112. Macklaim J. M. Clemente J. C. Knight R. Gloor G. B. Reid G. (2015). Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microb. Ecol. Health Dis. 26: 27799. 10.3402/mehd.v26.27799 26282697 PMC4539393 · DOI · Paper page
  113. Mackos A. R. Eubank T. D. Parry N. M. Bailey M. T. (2013). Probiotic Lactobacillus reuteri attenuates the stressor-enhanced severity of Citrobacter rodentium infection. Infect. Immun. 81 3253– 3263. 10.1128/IAI.00278-13 23798531 PMC3754198 · DOI · Paper page
  114. Mackos A. R. Galley J. D. Eubank T. D. Easterling R. S. Parry N. M. Fox J. G. (2016). Social stress-enhanced severity of Citrobacter rodentium-induced colitis is CCL2-dependent and attenuated by probiotic Lactobacillus reuteri. Mucosal Immunol. 9 515– 526. 10.1038/mi.2015.81 26422754 PMC4794400 · DOI
  115. Mangalat N. Liu Y. Fatheree N. Y. Ferris M. J. Van Arsdall M. R. Chen Z. (2012). Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. PLoS One 7: e43910. 10.1371/journal.pone.0043910 22970150 PMC3435331 · DOI
  116. Markle J. G. Frank D. N. Mortin-Toth S. Robertson C. E. Feazel L. M. Rolle-Kampczyk U. (2013). Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339 1084– 1088. 10.1126/science.1233521 23328391 · DOI · Paper page
  117. Martoni C. J. Labbe A. Ganopolsky J. G. Prakash S. Jones M. L. (2015). Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242. Gut Microbes 6 57– 65. 10.1080/19490976.2015.1005474 25612224 PMC4615650 · DOI · Paper page
  118. McFall-Ngai M. (2007). Adaptive immunity: care for the community. Nature 445: 153. 10.1038/445153a 17215830 · DOI
  119. McMillan A. Dell M. Zellar M. P. Cribby S. Martz S. Hong E. (2011). Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces 86 58– 64. 10.1016/j.colsurfb.2011.03.016 21497071 · DOI
  120. McVey Neufeld K. A. Mao Y. K. Bienenstock J. Foster J. A. Kunze W. A. (2013). The microbiome is essential for normal gut intrinsic primary afferent neuron excitability in the mouse. Neurogastroenterol. Motil. 25 e183– e188. 10.1111/nmo.12049 23181420 · DOI · Paper page
  121. Mehling H. Busjahn A. (2013). Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass) as a new approach to Helicobacter pylori control in humans. Nutrients 5 3062– 3073. 10.3390/nu5083062 23917169 PMC3775242 · DOI
  122. Mi G. L. Zhao L. Qiao D. D. Kang W. Q. Tang M. Q. Xu J. K. (2015). Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie Van Leeuwenhoek 107 1547– 1553. 10.1007/s10482-015-0448-9 25876529 · DOI
  123. Million M. Angelakis E. Maraninchi M. Henry M. Giorgi R. Valero R. (2013a). Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli. Int. J. Obes. 37 1460– 1466. 10.1038/ijo.2013.20 23459324 PMC3826031 · DOI · Paper page
  124. Million M. Maraninchi M. Henry M. Armougom F. Richet H. Carrieri P. (2012). Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii. Int. J. Obes. 36 817– 825. 10.1038/ijo.2011.153 21829158 PMC3374072 · DOI
  125. Million M. Thuny F. Angelakis E. Casalta J. P. Giorgi R. Habib G. (2013b). Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr. Diabetes 3: e87. 10.1038/nutd.2013.28 24018615 PMC3789131 · DOI
  126. Miniello V. L. Brunetti L. Tesse R. Natile M. Armenio L. Francavilla R. (2010). Lactobacillus reuteri modulates cytokines production in exhaled breath condensate of children with atopic dermatitis. J. Pediatr. Gastroenterol. Nutr. 50 573– 576. 10.1097/MPG.0b013e3181bb343f 20639717 · DOI
  127. Mishra S. K. Malik R. K. Manju G. Pandey N. Singroha G. Behare P. (2012). Characterization of a reuterin-producing Lactobacillus reuteri BPL-36 strain isolated from human infant fecal sample. Probiotics Antimicrob. Proteins 4 154– 161. 10.1007/s12602-012-9103-1 26782041 · DOI
  128. Mobini R. Tremaroli V. Stahlman M. Karlsson F. Levin M. Ljungberg M. (2017). Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 19 579– 589. 10.1111/dom.12861 28009106 · DOI
  129. Molina V. C. Medici M. Taranto M. P. Font de Valdez G. (2009). Lactobacillus reuteri CRL 1098 prevents side effects produced by a nutritional vitamin B deficiency. J. Appl. Microbiol. 106 467– 473. 10.1111/j.1365-2672.2008.04014.x 19200314 · DOI
  130. Montalban-Arques A. De Schryver P. Bossier P. Gorkiewicz G. Mulero V. Gatlin D. M. (2015). Selective manipulation of the gut microbiota improves immune status in vertebrates. Front. Immunol. 6: 512. 10.3389/fimmu.2015.00512 26500650 PMC4598590 · DOI
  131. Morita H. Toh H. Fukuda S. Horikawa H. Oshima K. Suzuki T. (2008). Comparative genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production. DNA Res. 15 151– 161. 10.1093/dnares/dsn009 18487258 PMC2650639 · DOI
  132. Mu Q. Kirby J. Reilly C. M. Luo X. M. (2017a). Leaky gut as a danger signal for autoimmune diseases. Front. Immunol. 8: 598. 10.3389/fimmu.2017.00598 28588585 PMC5440529 · DOI
  133. Mu Q. Tavella V. J. Kirby J. L. Cecere T. E. Chung M. Lee J. (2017b). Antibiotics ameliorate lupus-like symptoms in mice. Sci. Rep. 7: 13675. 10.1038/s41598-017-14223-0 29057975 PMC5651817 · DOI
  134. Mu Q. Zhang H. Liao X. Lin K. Liu H. Edwards M. R. (2017c). Control of lupus nephritis by changes of gut microbiota. Microbiome 5: 73. 10.1186/s40168-017-0300-8 28697806 PMC5505136 · DOI
  135. Mu Q. Zhang H. Luo X. M. (2015). SLE: another autoimmune disorder influenced by microbes and diet? Front. Immunol. 6: 608. 10.3389/fimmu.2015.00608 26648937 PMC4663251 · DOI
  136. Mukai T. Asasaka T. Sato E. Mori K. Matsumoto M. Ohori H. (2002). Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol. Med. Microbiol. 32 105– 110. 10.1111/j.1574-695X.2002.tb00541.x 11821231 · DOI · Paper page
  137. Nagpal R. Tsuji H. Takahashi T. Kawashima K. Nagata S. Nomoto K. (2016). Sensitive quantitative analysis of the meconium bacterial microbiota in healthy term infants born vaginally or by cesarean section. Front. Microbiol. 7: 1997 10.3389/fmicb.2016.01997 PMC5156933 28018325 · DOI
  138. Navarro J. B. Mashburn-Warren L. Bakaletz L. O. Bailey M. T. Goodman S. D. (2017). Enhanced probiotic potential of Lactobacillus reuteri when delivered as a biofilm on dextranomer microspheres that contain beneficial cargo. Front. Microbiol. 8: 489. 10.3389/fmicb.2017.00489 28396655 PMC5366311 · DOI
  139. Nguyen N. T. Hanieh H. Nakahama T. Kishimoto T. (2013). The roles of aryl hydrocarbon receptor in immune responses. Int. Immunol. 25 335– 343. 10.1093/intimm/dxt011 23580432 · DOI
  140. Oh P. L. Benson A. K. Peterson D. A. Patil P. B. Moriyama E. N. Roos S. (2010). Diversification of the gut symbiont Lactobacillus reuteri as a result of host-driven evolution. ISME J. 4 377– 387. 10.1038/ismej.2009.123 19924154 · DOI
  141. Ojetti V. Bruno G. Ainora M. E. Gigante G. Rizzo G. Roccarina D. (2012). Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol. Res. Pract. 2012: 740381. 10.1155/2012/740381 22690211 PMC3368352 · DOI
  142. Okeke F. Roland B. C. Mullin G. E. (2014). The role of the gut microbiome in the pathogenesis and treatment of obesity. Glob. Adv. Health Med. 3 44– 57. 10.7453/gahmj.2014.018 24891993 PMC4030605 · DOI
  143. Olson J. K. Rager T. M. Navarro J. B. Mashburn-Warren L. Goodman S. D. Besner G. E. (2016). Harvesting the benefits of biofilms: a novel probiotic delivery system for the prevention of necrotizing enterocolitis. J. Pediatr. Surg. 51 936– 941. 10.1016/j.jpedsurg.2016.02.062 27032609 · DOI
  144. Oncel M. Y. Sari F. N. Arayici S. Guzoglu N. Erdeve O. Uras N. (2014). Lactobacillus reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch. Dis. Child. Fetal Neonatal Ed. 99 F110– F115. 10.1136/archdischild-2013-304745 24309022 · DOI
  145. Pallin A. Agback P. Jonsson H. Roos S. (2016). Evaluation of growth, metabolism and production of potentially bioactive components during fermentation of barley with Lactobacillus reuteri. Food Microbiol. 57 159– 171. 10.1016/j.fm.2016.02.011 27052715 · DOI
  146. Park S. K. Park D. I. Choi J. S. Kang M. S. Park J. H. Kim H. J. (2007). The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology 54 2032– 2036. 18251154
  147. Petricevic L. Unger F. M. Viernstein H. Kiss H. (2008). Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. 141 54– 57. 10.1016/j.ejogrb.2008.06.003 18701205 · DOI
  148. Piyathilake C. J. Ollberding N. J. Kumar R. Macaluso M. Alvarez R. D. Morrow C. D. (2016). Cervical microbiota associated with higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. Cancer Prev. Res. 9 357– 366. 10.1158/1940-6207.CAPR-15-0350 26935422 PMC4869983 · DOI
  149. Preidis G. A. Saulnier D. M. Blutt S. E. Mistretta T. A. Riehle K. P. Major A. M. (2012). Host response to probiotics determined by nutritional status of rotavirus-infected neonatal mice. J. Pediatr. Gastroenterol. Nutr. 55 299– 307. 10.1097/MPG.0b013e31824d2548 22343914 PMC4010314 · DOI
  150. Raynaud C. Sarcabal P. Meynial-Salles I. Croux C. Soucaille P. (2003). Molecular characterization of the 1,3-propanediol (1,3-PD) operon of Clostridium butyricum. Proc. Natl. Acad. Sci. U.S.A. 100 5010– 5015. 10.1073/pnas.0734105100 12704244 PMC154289 · DOI
  151. Reid G. Burton J. (2002). Use of Lactobacillus to prevent infection by pathogenic bacteria. Microbes Infect. 4 319– 324. 10.1016/S1286-4579(02)01544-7 11909742 · DOI
  152. Rojas M. A. Lozano J. M. Rojas M. X. Rodriguez V. A. Rondon M. A. Bastidas J. A. (2012). Prophylactic probiotics to prevent death and nosocomial infection in preterm infants. Pediatrics 130 e1113– e1120. 10.1542/peds.2011-3584 23071204 · DOI
  153. Romani Vestman N. Chen T. Lif Holgerson P. Ohman C. Johansson I. (2015). Oral microbiota shift after 12-week supplementation with Lactobacillus reuteri DSM 17938 and PTA 5289; a randomized control trial. PLoS One 10: e0125812. 10.1371/journal.pone.0125812 25946126 PMC4422650 · DOI · Paper page
  154. Roos S. Dicksved J. Tarasco V. Locatelli E. Ricceri F. Grandin U. (2013). 454 pyrosequencing analysis on faecal samples from a randomized DBPC trial of colicky infants treated with Lactobacillus reuteri DSM 17938. PLoS One 8: e56710. 10.1371/journal.pone.0056710 23468874 PMC3585302 · DOI
  155. Roos S. Jonsson H. (2002). A high-molecular-mass cell-surface protein from Lactobacillus reuteri 1063 adheres to mucus components. Microbiology 148(Pt 2) 433– 442. 10.1099/00221287-148-2-433 11832507 · DOI
  156. Rosenfeldt V. Benfeldt E. Nielsen S. D. Michaelsen K. F. Jeppesen D. L. Valerius N. H. (2003). Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111 389– 395. 10.1067/mai.2003.389 12589361 · DOI
  157. Rosenfeldt V. Benfeldt E. Valerius N. H. Paerregaard A. Michaelsen K. F. (2004). Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J. Pediatr. 145 612– 616. 10.1016/j.jpeds.2004.06.068 15520759 · DOI
  158. Rosenfeldt V. Michaelsen K. F. Jakobsen M. Larsen C. N. Moller P. L. Pedersen P. (2002a). Effect of probiotic Lactobacillus strains in young children hospitalized with acute diarrhea. Pediatr. Infect. Dis. J. 21 411– 416. 10.1097/00006454-200205000-00012 12150178 · DOI
  159. Rosenfeldt V. Michaelsen K. F. Jakobsen M. Larsen C. N. Moller P. L. Tvede M. (2002b). Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr. Infect. Dis. J. 21 417– 419. 12150179
  160. Rossi F. Gardini F. Rizzotti L. La Gioia F. Tabanelli G. Torriani S. (2011). Quantitative analysis of histidine decarboxylase gene (hdcA) transcription and histamine production by Streptococcus thermophilus PRI60 under conditions relevant to cheese making. Appl. Environ. Microbiol. 77 2817– 2822. 10.1128/AEM.02531-10 21378060 PMC3126354 · DOI
  161. Salas-Jara M. J. Ilabaca A. Vega M. Garcia A. (2016). Biofilm forming Lactobacillus: new challenges for the development of probiotics. Microorganisms 4: E35. 10.3390/microorganisms4030035 27681929 PMC5039595 · DOI
  162. Santos F. Spinler J. K. Saulnier D. M. Molenaar D. Teusink B. de Vos W. M. (2011). Functional identification in Lactobacillus reuteri of a PocR-like transcription factor regulating glycerol utilization and vitamin B12 synthesis. Microb. Cell Fact. 10: 55. 10.1186/1475-2859-10-55 21777454 PMC3162504 · DOI
  163. Santos F. Vera J. L. van der Heijden R. Valdez G. de Vos W. M. Sesma F. (2008a). The complete coenzyme B12 biosynthesis gene cluster of Lactobacillus reuteri CRL1098. Microbiology 154(Pt 1) 81– 93. 10.1099/mic.0.2007/011569-0 18174128 · DOI
  164. Santos F. Wegkamp A. de Vos W. M. Smid E. J. Hugenholtz J. (2008b). High-Level folate production in fermented foods by the B12 producer Lactobacillus reuteri JCM1112. Appl. Environ. Microbiol. 74 3291– 3294. 10.1128/AEM.02719-07 18344331 PMC2394963 · DOI
  165. Savino F. Cordisco L. Tarasco V. Palumeri E. Calabrese R. Oggero R. (2010). Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 126 e526– e533. 10.1542/peds.2010-0433 20713478 · DOI
  166. Savino F. Fornasero S. Ceratto S. De Marco A. Mandras N. Roana J. (2015b). Probiotics and gut health in infants: a preliminary case-control observational study about early treatment with Lactobacillus reuteri DSM 17938. Clin. Chim. Acta 451(Pt A) 82– 87. 10.1016/j.cca.2015.02.027 25704298 · DOI
  167. Savino F. Pelle E. Palumeri E. Oggero R. Miniero R. (2007). Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119 e124– e130. 10.1542/peds.2006-1222 17200238 · DOI
  168. Scaccianoce G. Zullo A. Hassan C. Gentili F. Cristofari F. Cardinale V. (2008). Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur. Rev. Med. Pharmacol. Sci. 12 251– 256. 18727457
  169. Scott K. P. Antoine J. M. Midtvedt T. van Hemert S. (2015). Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 26: 25877. 10.3402/mehd.v26.25877 25651995 PMC4315778 · DOI
  170. Seo B. J. Mun M. R. J R. K. Kim C. J. Lee I. Chang Y. H. (2010). Bile tolerant Lactobacillus reuteri isolated from pig feces inhibits enteric bacterial pathogens and porcine rotavirus. Vet. Res. Commun. 34 323– 333. 10.1007/s11259-010-9357-6 20396947 · DOI
  171. Shi L. H. Balakrishnan K. Thiagarajah K. Mohd Ismail N. I. Yin O. S. (2016). Beneficial properties of probiotics. Trop. Life Sci. Res. 27 73– 90. 10.21315/tlsr2016.27.2.6 27688852 PMC5031164 · DOI
  172. Shornikova A. V. Casas I. A. Isolauri E. Mykkanen H. Vesikari T. (1997a). Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J. Pediatr. Gastroenterol. Nutr. 24 399– 404. 9144122
  173. Shornikova A. V. Casas I. A. Mykkanen H. Salo E. Vesikari T. (1997b). Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 16 1103– 1107. 9427453
  174. Sims I. M. Frese S. A. Walter J. Loach D. Wilson M. Appleyard K. (2011). Structure and functions of exopolysaccharide produced by gut commensal Lactobacillus reuteri 100-23. ISME J. 5 1115– 1124. 10.1038/ismej.2010.201 21248858 PMC3146279 · DOI
  175. Sinkiewicz G. (2010). Lactobacillus reuteri in Health and Disease. Doctoral dissertation, Malmö University Malmö.
  176. Soto A. Martin V. Jimenez E. Mader I. Rodriguez J. M. Fernandez L. (2014). Lactobacilli and bifidobacteria in human breast milk: influence of antibiotherapy and other host and clinical factors. J. Pediatr. Gastroenterol. Nutr. 59 78– 88. 10.1097/MPG.0000000000000347 24590211 PMC4086764 · DOI
  177. Spinler J. K. Taweechotipatr M. Rognerud C. L. Ou C. N. Tumwasorn S. Versalovic J. (2008). Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14 166– 171. 10.1016/j.anaerobe.2008.02.001 18396068 PMC2494590 · DOI
  178. Sriramulu D. D. Liang M. Hernandez-Romero D. Raux-Deery E. Lunsdorf H. Parsons J. B. (2008). Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol dehydratase in metabolosomes and metabolizes 1,2-propanediol by disproportionation. J. Bacteriol. 190 4559– 4567. 10.1128/JB.01535-07 18469107 PMC2446795 · DOI · Paper page
  179. Stensson M. Koch G. Coric S. Abrahamsson T. R. Jenmalm M. C. Birkhed D. (2014). Oral administration of Lactobacillus reuteri during the first year of life reduces caries prevalence in the primary dentition at 9 years of age. Caries Res. 48 111– 117. 10.1159/000354412 24296746 · DOI
  180. Stevens J. F. Maier C. S. (2008). Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease. Mol. Nutr. Food Res. 52 7– 25. 10.1002/mnfr.200700412 18203133 PMC2423340 · DOI
  181. Stevens M. J. Vollenweider S. Meile L. Lacroix C. (2011). 1,3-Propanediol dehydrogenases in Lactobacillus reuteri: impact on central metabolism and 3-hydroxypropionaldehyde production. Microb. Cell Fact. 10: 61. 10.1186/1475-2859-10-61 21812997 PMC3180264 · DOI
  182. Su M. S. Ganzle M. G. (2014). Novel two-component regulatory systems play a role in biofilm formation of Lactobacillus reuteri rodent isolate 100-23. Microbiology 160(Pt 4) 795– 806. 10.1099/mic.0.071399-0 24509500 · DOI
  183. Su M. S. Schlicht S. Ganzle M. G. (2011). Contribution of glutamate decarboxylase in Lactobacillus reuteri to acid resistance and persistence in sourdough fermentation. Microb. Cell Fact. 10(Suppl. 1): S8. 10.1186/1475-2859-10-S1-S8 21995488 PMC3231934 · DOI
  184. Su Y. Chen X. Liu M. Guo X. (2017). Effect of three lactobacilli with strain-specific activities on the growth performance, faecal microbiota and ileum mucosa proteomics of piglets. J. Anim. Sci. Biotechnol. 8: 52. 10.1186/s40104-017-0183-3 28616225 PMC5466754 · DOI
  185. Sung V. Hiscock H. Tang M. L. Mensah F. K. Nation M. L. Satzke C. (2014). Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 348: g2107. 10.1136/bmj.g2107 24690625 PMC3972414 · DOI
  186. Szajewska H. Gyrczuk E. Horvath A. (2013). Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J. Pediatr. 162 257– 262. 10.1016/j.jpeds.2012.08.004 22981952 · DOI
  187. Talarico T. L. Casas I. A. Chung T. C. Dobrogosz W. J. (1988). Production and isolation of reuterin, a growth inhibitor produced by Lactobacillus reuteri. Antimicrob. Agents Chemother. 32 1854– 1858. 10.1128/AAC.32.12.1854 3245697 PMC176032 · DOI
  188. Talarico T. L. Dobrogosz W. J. (1989). Chemical characterization of an antimicrobial substance produced by Lactobacillus reuteri. Antimicrob. Agents Chemother. 33 674– 679. 10.1128/AAC.33.5.674 2751282 PMC172512 · DOI
  189. Talarico T. L. Dobrogosz W. J. (1990). Purification and characterization of glycerol dehydratase from Lactobacillus reuteri. Appl. Environ. Microbiol. 56 1195– 1197. 16348166 PMC184372
  190. Taranto M. P. Vera J. L. Hugenholtz J. De Valdez G. F. Sesma F. (2003). Lactobacillus reuteri CRL1098 produces cobalamin. J. Bacteriol. 185 5643– 5647. 10.1128/JB.185.18.5643-5647.2003 12949118 PMC193752 · DOI
  191. Thomas C. M. Hong T. van Pijkeren J. P. Hemarajata P. Trinh D. V. Hu W. (2012). Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 7: e31951. 10.1371/journal.pone.0031951 22384111 PMC3285189 · DOI · Paper page
  192. Thomas C. M. Saulnier D. M. Spinler J. K. Hemarajata P. Gao C. Jones S. E. (2016). FolC2-mediated folate metabolism contributes to suppression of inflammation by probiotic Lactobacillus reuteri. Microbiologyopen 5 802– 818. 10.1002/mbo3.371 27353144 PMC5061717 · DOI
  193. Tsokos G. C. (2011). Systemic lupus erythematosus. N. Engl. J. Med. 365 2110– 2121. 10.1056/NEJMra1100359 22129255 · DOI
  194. Tubelius P. Stan V. Zachrisson A. (2005). Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ. Health 4: 25. 10.1186/1476-069X-4-25 16274475 PMC1298318 · DOI
  195. Tzang B. S. Liu C. H. Hsu K. C. Chen Y. H. Huang C. Y. Hsu T. C. (2017). Effects of oral Lactobacillus administration on antioxidant activities and CD4+CD25+forkhead box P3 (FoxP3)+ T cells in NZB/W F1 mice. Br. J. Nutr. 118 333– 342. 10.1017/S0007114517002112 28901888 · DOI
  196. Valeur N. Engel P. Carbajal N. Connolly E. Ladefoged K. (2004). Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl. Environ. Microbiol. 70 1176– 1181. 10.1128/AEM.70.2.1176-1181.2004 14766603 PMC348788 · DOI
  197. Walter J. Britton R. A. Roos S. (2011). Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm. Proc. Natl. Acad. Sci. U.S.A. 108(Suppl. 1) 4645– 4652. 10.1073/pnas.1000099107 20615995 PMC3063604 · DOI
  198. Walter J. Chagnaud P. Tannock G. W. Loach D. M. Dal Bello F. Jenkinson H. F. (2005). A high-molecular-mass surface protein (Lsp) and methionine sulfoxide reductase B (MsrB) contribute to the ecological performance of Lactobacillus reuteri in the murine gut. Appl. Environ. Microbiol. 71 979– 986. 10.1128/AEM.71.2.979-986.2005 15691956 PMC546760 · DOI
  199. Walter J. Loach D. M. Alqumber M. Rockel C. Hermann C. Pfitzenmaier M. (2007). D-alanyl ester depletion of teichoic acids in Lactobacillus reuteri 100-23 results in impaired colonization of the mouse gastrointestinal tract. Environ. Microbiol. 9 1750– 1760. 10.1111/j.1462-2920.2007.01292.x 17564608 · DOI
  200. Walter J. Schwab C. Loach D. M. Ganzle M. G. Tannock G. W. (2008). Glucosyltransferase A (GtfA) and inulosucrase (Inu) of Lactobacillus reuteri TMW1.106 contribute to cell aggregation, in vitro biofilm formation, and colonization of the mouse gastrointestinal tract. Microbiology 154(Pt 1) 72– 80. 10.1099/mic.0.2007/010637-0 18174127 · DOI

200 of 216 shown

Cited by

Sorted by citations

Authors
Mu, Q., Tavella, V. J., & Luo, X. M.
Affiliations
Virginia–Maryland College of Veterinary Medicine (US)
Corresponding author
Luo, Xin M.
ORCID
Venue
Frontiers in Microbiology
Publisher
Frontiers Media SA
Published
2018-04-19
Volume
9
Pages
757-757
ISSN
1664-302X (ISSN-L)
DOI
10.3389/fmicb.2018.00757
PMC
PMC5917019
OpenAlex
W2795389370
Cited by
744
References
20
Citations by year
2026: 78 · 2025: 116 · 2024: 104 · 2023: 115 · 2022: 118 · 2021: 102 · 2020: 71 · 2019: 32 · 2018: 7
FWCI
5.38
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Microbiology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • VTechWorks (Virginia Tech) (submittedVersion, cc-by)
Funders
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR067418)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
Lactobacillus reuteri, probiotics, gut microbiota, antimicrobial activity, reuterin, organic acids, immunomodulation, regulatory T cells, inflammatory cytokines, intestinal barrier, microbial translocation, inflammatory diseases, prebiotics, breast milk, urinary tract colonization, skin colonization

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review